The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins
Abstract
Adverse immune responses severely hamper the success of biopharmaceutical therapies. Possible clinical consequences include anaphylaxis, reduced drug half‐life and neutralization of the therapeutic protein as well as the endogenous human homologue. Controlling potential triggers of the immune system helps to minimize the immunogenicity of biopharmaceuticals, a crucial consideration in biopharmaceutical manufacturing. This review summarizes the latest advancements that have been made towards insight into the impact of structural characteristics on the immunogenicity of therapeutic proteins. Examples are given to illustrate the role of critical quality attributes, such as protein conformation, glycosylation, chemical modifications and aggregation, in immunogenicity. During the development of biopharmaceutical products, it is important to not just assess the risk for immunogenicity in clinical trials, but to ensure product quality throughout drug design, cell‐line selection, upstream and downstream processing, all the way to to the final product.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Effects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355
Immunogenicity of protein therapeutics: The key causes, consequences and challenges
Baker, M., Reynolds, H. M., Lumicisi, B., & Bryson, C. J. (2010) · Self/Nonself · doi:10.4161/self.1.4.13904 · Cited by 372
Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins
Ghaderi, D., Taylor, R. E., Padler-Karavani, V., Diaz, S., & Varki, A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1651 · Cited by 372
Impact of Product-Related Factors on Immunogenicity of Biotherapeutics
Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350 · cited 3×
“Yet, it is believed that PEGylation is more likely to reduce the immunogenicity of non-human proteins [13].”
BackgroundStrategies for the assessment of protein aggregates in pharmaceutical biotech product development
den Engelsman, J., Garidel, P., Smulders, R., Koll, H., Smith, B., Bassarab, S., Seidl, A., Hainzl, O., & Jiskoot, W. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0297-1 · Cited by 348
Runkel, L., Meier, W., Pepinsky, R. B., Karpusas, M., Whitty, A., Kimball, K., Brickelmaier, M., Muldowney, C., Jones, W., & Goelz, S. E. (1998) · Pharmaceutical Research · doi:10.1023/a:1011974512425 · Cited by 304
Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy
Chung, C. H. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0012 · Cited by 278
Eon‐Duval, A., Broly, H., & Gleixner, R. (2012) · Biotechnology Progress · doi:10.1002/btpr.1548 · Cited by 234 · cited 2×
“Product related factors that influence immunogenicity are part of the critical quality attributes of proteins, which are defined as those characteristics that potentially impact safety and efficacy and should be kept within a certain range to ensure product quality [14, 15].”
BackgroundPotential impact of the non‐human sialic acid N‐glycolylneuraminic acid on transplant rejection risk
Padler‐Karavani, V., & Varki, A. (2011) · Xenotransplantation · doi:10.1111/j.1399-3089.2011.00622.x · Cited by 162 · cited 1×
“2% of circulating immunoglobulin [40]).”
Cited by
Perfusion mammalian cell culture for recombinant protein manufacturing – A critical review
Bielser, J.-M., Wolf, M., Souquet, J., Broly, H., & Morbidelli, M. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.04.011 · Cited by 263
Toward Biotherapeutic Product Real‐Time Quality Monitoring
Guerra, A., von Stosch, M., & Glassey, J. (2019) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2018.1524362 · Cited by 58
“Aggregates and mAbs fragments potentially induce adverse toxicological and immunological responses [65].”
BackgroundChisholm, C. F., Soucie, K. R., Song, J. S., Strauch, P., Torres, R. M., Carpenter, J. F., Ragheb, J. A., & Randolph, T. W. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.02.008 · Cited by 31
Real‐Time Detection of mAb Aggregates in an Integrated Downstream Process
São Pedro, M. N., Isaksson, M., Gomis‐Fons, J., Eppink, M. H. M., Nilsson, B., & Ottens, M. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28466 · Cited by 16
Metadata
- Authors
- van Beers, M. M. C., & Bardor, M.
- Venue
- Biotechnology Journal
- Publisher
- Wiley
- Published
- 2012-10-02
- Volume
- 7
- Issue
- 12
- Pages
- 1473-1484
- ISSN
- 1860-6768 (ISSN-L)
- 1860-7314
- OpenAlex
- W2125845245
- Cited by
- 172
- References
- 11
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins. https://app.cochat.ai/papers/10.1002/biot.201200065
- The paper
- van Beers, M. M. C., & Bardor, M. (2012). Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins. Biotechnology Journal. https://doi.org/10.1002/biot.201200065
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.